Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 7
1976 6
1977 26
1978 11
1979 21
1980 18
1981 24
1982 26
1983 35
1984 18
1985 50
1986 68
1987 57
1988 80
1989 62
1990 101
1991 84
1992 64
1993 79
1994 64
1995 62
1996 46
1997 54
1998 55
1999 37
2000 36
2001 35
2002 45
2003 46
2004 52
2005 48
2006 34
2007 44
2008 47
2009 34
2010 25
2011 25
2012 41
2013 42
2014 38
2015 19
2016 17
2017 14
2018 14
2019 8
2020 6
2021 6
2022 2
2023 7
2024 4
2025 6
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,794 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Does atenolol use during pregnancy cause small for gestational age neonates? A meta-analysis.
Bratton S, Taylor MK, Cortez P, Schiattarella A, Fochesato C, Sisti G. Bratton S, et al. J Perinat Med. 2024 Aug 8;52(8):858-862. doi: 10.1515/jpm-2024-0114. Print 2024 Oct 28. J Perinat Med. 2024. PMID: 39115600
OBJECTIVES: Atenolol is a commonly used beta bloscker in non-pregnant women. Many providers are hesitant in prescribing atenolol in pregnancy because of a possible association with poor fetal growth. ...A study by Duan et al. in 2018 noted the following rate of smal …
OBJECTIVES: Atenolol is a commonly used beta bloscker in non-pregnant women. Many providers are hesitant in prescribing atenolol …
Atenolol in hypertension: is it a wise choice?
Carlberg B, Samuelsson O, Lindholm LH. Carlberg B, et al. Lancet. 2004 Nov 6-12;364(9446):1684-9. doi: 10.1016/S0140-6736(04)17355-8. Lancet. 2004. PMID: 15530629
FINDINGS: We identified four studies that compared atenolol with placebo or no treatment, and five that compared atenolol with other antihypertensive drugs. ...Moreover, cardiovascular mortality also tended to be higher with atenolol treatment than with other …
FINDINGS: We identified four studies that compared atenolol with placebo or no treatment, and five that compared atenolol with …
Atenolol vs nonatenolol beta-blockers for the treatment of hypertension: a meta-analysis.
Kuyper LM, Khan NA. Kuyper LM, et al. Can J Cardiol. 2014 May;30(5 Suppl):S47-53. doi: 10.1016/j.cjca.2014.01.006. Epub 2014 Jan 15. Can J Cardiol. 2014. PMID: 24750981 Free article. Review.
CONCLUSIONS: In the young, both atenolol and nonatenolol beta-blockers are effective in reducing cardiovascular end points for hypertension without compelling indications. Atenolol is associated with increased stroke in the elderly but whether this extends to nonate …
CONCLUSIONS: In the young, both atenolol and nonatenolol beta-blockers are effective in reducing cardiovascular end points for hypert …
Efficacy and safety of oral atenolol for the treatment of infantile haemangioma: A systematic review.
Wang Q, Xiang B, Chen S, Ji Y. Wang Q, et al. Australas J Dermatol. 2019 Aug;60(3):181-185. doi: 10.1111/ajd.12966. Epub 2018 Dec 4. Australas J Dermatol. 2019. PMID: 30515761
Recently, several studies have reported their experience in using oral atenolol in patients with infantile haemangioma (IH), especially as an alternative to propranolol, but the efficacy and safety of oral atenolol has not been evaluated. ...Among the 341 patients, …
Recently, several studies have reported their experience in using oral atenolol in patients with infantile haemangioma (IH), especial …
Should Propranolol Remain the Gold Standard for Treatment of Infantile Hemangioma? A Systematic Review and Meta-Analysis of Propranolol Versus Atenolol.
Chen T, Gudipudi R, Nguyen SA, Carroll W, Clemmens C. Chen T, et al. Ann Otol Rhinol Laryngol. 2023 Mar;132(3):332-340. doi: 10.1177/00034894221089758. Epub 2022 Apr 25. Ann Otol Rhinol Laryngol. 2023. PMID: 35466712
BACKGROUND: Although propranolol has been established as the gold standard when treatment is sought for infantile hemangioma, concerns over its side effect profile have led to increasing usage of atenolol, a beta-1 selective blocker. METHODS: A systematic review of PubMed, …
BACKGROUND: Although propranolol has been established as the gold standard when treatment is sought for infantile hemangioma, concerns over …
Atenolol eye drops.
Phillips CI, Macdonald M, Gore SM, Cullen PM. Phillips CI, et al. Br Med J. 1976 Dec 11;2(6049):1448. doi: 10.1136/bmj.2.6049.1448-b. Br Med J. 1976. PMID: 12855 Free PMC article. Clinical Trial. No abstract available.
A meta-analytical comparison of atenolol with angiotensin-converting enzyme inhibitors on arterial stiffness, peripheral blood pressure and heart rate in hypertensive patients.
Xie H, Luo G, Zheng Y, Peng F, Xie L. Xie H, et al. Clin Exp Hypertens. 2017;39(5):421-426. doi: 10.1080/10641963.2016.1267188. Epub 2017 May 23. Clin Exp Hypertens. 2017. PMID: 28534649 Free article. Review.
Overall changes in PWV (weighted mean difference or WMD = 0.068, 95% confidence interval or CI: -0.487 to -0.623, P = 0.811) and peripheral systolic blood pressure (PSBP) (WMD = -1.281 mmHg, 95% CI: -6.936 to 4.375, P = 0.657) did not differ significantly between atenolol …
Overall changes in PWV (weighted mean difference or WMD = 0.068, 95% confidence interval or CI: -0.487 to -0.623, P = 0.811) and peripheral …
Bioavailability of atenolol formulations.
Mcainsh J, Simpson WT, Holmes BF, Young J, Ellis SH. Mcainsh J, et al. Biopharm Drug Dispos. 1980 Oct-Dec;1(6):323-32. doi: 10.1002/bdd.2510010604. Biopharm Drug Dispos. 1980. PMID: 7459427 Clinical Trial.
In this comparative bioavailability study two tablet formulations of atenolol (sales and clinical trial) were compared with an oral solution. Twelve healthy adult male volunteers received, on a cross-over basis, on three separate occasions, 100 mg oral dose of the three fo …
In this comparative bioavailability study two tablet formulations of atenolol (sales and clinical trial) were compared with an oral s …
Bioequivalence Study of Atenolol Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions.
Li Y, Huang Y, Fu X, Xia J, Su J, Gu W, Liu W, Jian J, Xu Z. Li Y, et al. Clin Pharmacol Drug Dev. 2024 Aug;13(8):870-875. doi: 10.1002/cpdd.1414. Epub 2024 May 14. Clin Pharmacol Drug Dev. 2024. PMID: 38742472 Clinical Trial.
Atenolol, a cardioselective beta1-blocker, exhibits efficacy in treating cardiovascular diseases. ...After administering a single oral dose of the test or reference formulation (25 mg), plasma atenolol concentrations were measured using liquid chromatography-tandem …
Atenolol, a cardioselective beta1-blocker, exhibits efficacy in treating cardiovascular diseases. ...After administering a single ora …
Atenolol once-daily in hypertension.
Jeffers TA, Webster J, Petrie JC, Barker NP. Jeffers TA, et al. Br J Clin Pharmacol. 1977 Oct;4(5):523-7. doi: 10.1111/j.1365-2125.1977.tb00780.x. Br J Clin Pharmacol. 1977. PMID: 334211 Free PMC article. Clinical Trial.
Each patient received atenolol (50 mg/day, 100 mg/day, 200 mg/day) and placebo according to a randomized sequence in a once-daily dose. Wash-out periods on a matching placebo were included between the treatment periods. 2 The effect of lying, standing and post-exercise blo …
Each patient received atenolol (50 mg/day, 100 mg/day, 200 mg/day) and placebo according to a randomized sequence in a once-daily dos …
1,794 results